15:26 , May 9, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Serum levels of miR-940, miR-451a, miR-16-5p and miR-17-3p could help predict response to Herceptin trastuzumab in HER2 (EGFR2; ErbB2; neu)-positive metastatic breast cancer patients. In 283 HER2-positive metastatic breast cancer patients receiving Herceptin,...
23:51 , Feb 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Renal

INDICATION: Polycystic kidney disease (PKD) Studies in patient samples and mice suggest inhibiting miR-17 could help treat autosomal dominant polycystic kidney disease (ADPKD). In patient kidney samples, levels of miR-17 were higher than in samples from...
01:00 , Feb 17, 2017 |  BC Innovations  |  Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc., Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and a...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer MicroRNA-17-92 (miR-17-92) Cell culture and mouse studies suggest inhibiting miR-17-92 could help treat medulloblastoma. In...
07:00 , Sep 1, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Retinoblastoma MicroRNA-17-92 (miR-17-92); miR-17; miR-20 Patient sample and mouse studies suggest inhibiting miRNAs encoded by the...